Australia markets close in 25 minutes
  • ALL ORDS

    7,232.20
    -49.90 (-0.69%)
     
  • ASX 200

    6,971.60
    -46.20 (-0.66%)
     
  • AUD/USD

    0.7716
    -0.0012 (-0.15%)
     
  • OIL

    62.61
    +0.17 (+0.27%)
     
  • GOLD

    1,784.70
    +6.30 (+0.35%)
     
  • BTC-AUD

    71,625.48
    -302.38 (-0.42%)
     
  • CMC Crypto 200

    1,268.92
    +34.50 (+2.80%)
     
  • AUD/EUR

    0.6411
    -0.0003 (-0.05%)
     
  • AUD/NZD

    1.0754
    -0.0016 (-0.15%)
     
  • NZX 50

    12,535.34
    -143.21 (-1.13%)
     
  • NASDAQ

    13,809.30
    -98.37 (-0.71%)
     
  • FTSE

    6,859.87
    -140.21 (-2.00%)
     
  • Dow Jones

    33,821.30
    -256.33 (-0.75%)
     
  • DAX

    15,129.51
    -238.88 (-1.55%)
     
  • Hang Seng

    28,660.50
    -475.23 (-1.63%)
     
  • NIKKEI 225

    28,516.86
    -583.52 (-2.01%)
     

Osmotica to Present at Barclays Global Healthcare Conference 2021

Osmotica Holdings US LLC
·1-min read

BRIDGEWATER, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Barclays Global Healthcare Conference 2021 as follows:

Date:

Tuesday, March 9, 2021

Time:

9:45 a.m. Eastern Time

Webcast:

https://kvgo.com/2021-global-healthcare-conference/osmotica-march-2021

About Osmotica Pharmaceuticals plc

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.

Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com